Immunotherapy maintenance therapy for advanced urothelial carcinoma (aUC): a comprehensive review.

Carril-Ajuria, Lucia; Martin-Soberón, Maria Cruz; de Velasco, Guillermo; Agarwal, Neeraj; Castellano, Daniel

Carril-Ajuria, Lucia; Martin-Soberón, Maria Cruz; de Velasco, Guillermo; Agarwal, Neeraj; Castellano, Daniel.

Affiliation

Carril-Ajuria L; Medical Oncology Department, University Hospital 12 de Octubre, Madrid, Spain.
Martin-Soberón MC; Medical Oncology Department, Institute Gustave Roussy, Villejuif, France.
de Velasco G; Medical Oncology Department, University Hospital 12 de Octubre, Madrid, Spain.
Agarwal N; Medical Oncology Department, University Hospital 12 de Octubre, Madrid, Spain.
Castellano D; Division of Medical Oncology, Department of Internal Medicine, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA.

J Cancer Res Clin Oncol ; 148(5): 1097-1105, 2022 May.

Article in En | MEDLINE | ID: mdl-35064817

Subject(s)

Antineoplastic Agents; Carcinoma, Transitional Cell; Urinary Bladder Neoplasms; Antineoplastic Agents/therapeutic use; Carcinoma, Transitional Cell/drug therapy; Carcinoma, Transitional Cell/pathology; Cisplatin/therapeutic use; Female; Humans; Immunologic Factors; Immunotherapy; Male; Platinum/therapeutic use; Urinary Bladder Neoplasms/drug therapy; Urinary Bladder Neoplasms/pathology

Key words

Advanced bladder cancer; Avelumab; Chemotherapy; Immune-checkpoint inhibitors; Maintenance therapy; Transitional cell cancer of the urothelium

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Database: MEDLINE Main subject: Urinary Bladder Neoplasms / Carcinoma, Transitional Cell / Antineoplastic Agents Type of study: Prognostic_studies Limits: Female / Humans / Male Language: En Year: 2022 Type: Article

Fulltext

XML

PubMed Links

Search on Google